bevacizumab
roche
['gyn', 'gog-0218', '5553', 'ovarian']
gyn poster #asco22 you ab 5553 p 432 id of ovarian cancer who are experiencing the highest benefit from bev in first-line setting based on their tumor intrinsic chemosensitivity (kelim): gog-0218 validation study trial confirms outcomes of icon-7 trial 1/2 #gyncsm
#ovca survivor; research advocate; author; co-moderator #gyncsm chat;  #ASCO22 Feature Voice  COI: https://t.co/AUF1EprNVt Opinions are my own.